OncBioMune Acquires Propolis Product Line for German Partner

BATON ROUGE, LA--(Marketwired - July 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce the acquisition of the rights to six Aagaard® Propolis products for the Mexican markets from the Company's German partner roha Arzneimittel GmbH ("roha"). OncBioMune has begun the process to market the products across Mexico, with expectations for an official launch during the fourth quarter of 2017.

OncBioMune has acquired from roha the Mexican rights to:

• Aagaard® Propolis Syrup
• Aagaard® Propolis Kids Lozenges
• Aagaard® Propolis Adult Lozenges
• Aagaard® Propolis Capsules
• Aagaard® Propolis Chewable Lozenges
• Aagaard® Propolis Royal Jelly and Vitamin C Capsules

Propolis, sometimes referred to as "bee glue," is a product rich in polyphenols called flavonoids produced by honey bees. Two main immunopotent chemicals in propolis have been identified as caffeic acid phenethyl ester (CAPE) and artepillin C, chemicals known to have a wide array of positive effects related to immunosuppression, macrophage function and more. More broadly, although scientific research is limited, propolis is believed to have antibacterial, antiviral, antifungal, and anti-inflammatory properties. The combination of benefits, along with strong bioavailability and a good historical safety profile, have resulted in propolis serving as the active ingredient in traditional medicines for thousands and years and in over-the-counter medical products sold globally today.

"roha sources only the best propolis from all over the world in creating their Aagaard® line. As a result, it is the number one seller of propolis-based products in Europe," commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. "We believe that we can have the products in from roha's state-of-the-art manufacturing facility and on shelves in Mexico for the flu season, which should provide a nice kick-start to our sales efforts that we estimate should generate approximately $300,000 in gross revenue annually."